Improvement of ventricular arrhythmia by octreotide treatment in acromegalic cardiomyopathy

Jpn Heart J. 2003 Nov;44(6):1027-31. doi: 10.1536/jhj.44.1027.

Abstract

We report a case of acromegalic cardiomyopathy in a 46-year-old Japanese man with pituitary adenoma. Increased secretion of growth hormone and insulin-like growth factor I were detected. He had left ventricular hypertrophy, impaired cardiac function, and frequent ventricular premature complexes. After 2-month treatment with octreotide, a long-acting somatostatin analogue, levels of both hormones were decreased. At the same time, left ventricular hypertrophy (intraventricular septal thickness: 22.5 to 17.8 mm), cardiac function (ejection fraction: 38 to 50%), and frequency of ventricular premature complexes (17,249 to 2,882 beats a day) were improved. Transsphenoidal surgery was then safely performed. Treatment with octreotide is thought to have some effect on improvement of ventricular arrhythmia in acromegalic heart.

Publication types

  • Case Reports

MeSH terms

  • Acromegaly / drug therapy*
  • Acromegaly / etiology
  • Acromegaly / physiopathology
  • Adenoma / complications
  • Arrhythmias, Cardiac / physiopathology*
  • Cardiac Complexes, Premature / physiopathology*
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / etiology
  • Cardiomyopathies / physiopathology
  • Human Growth Hormone / metabolism
  • Humans
  • Hypertrophy, Left Ventricular / physiopathology
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Middle Aged
  • Octreotide / therapeutic use*
  • Pituitary Neoplasms / complications
  • Somatostatin / agonists*
  • Ventricular Function, Left / physiology

Substances

  • Human Growth Hormone
  • Somatostatin
  • Insulin-Like Growth Factor I
  • Octreotide